Protagonist Therapeutics Gains $40M
Milpitas-based Protagonist Therapeutics, which is developing biotherapeutics aimed at treating inflammatory bowel disease, has raised $40M in a Series C funding. The funding was led by Canaan Partners, and also included Adage Capital Management, RA Capital Management and Foresite Capital, along with Johnson & Johnson Innovation - JJDC, Lilly Ventures, Pharmstandard International, and Starfish Ventures. Protagonist Therapeutics is developing orally stable peptide therapeutics, initially aimed at treating inflammatory bowel disease; the company's compounds are an alternative to current therapy, which requires an injection regime.
posted on Friday, July 17, 2015 (Link to more information)
Related companies:
Protagonist Therapeutics Inc
Related stories:
> Protagonist Therapeutics Debuts In IPO
> Protagonist Therapeutics Gets $22M In PIPE
> Nuon Therapeutics Gains $5M
> Pearl Therapeutics Gains $65M
> Sorbent Therapeutics Gains $36M
silicontap.com Home